Use of biologics in pregnancy: limitations stemming from clinical trials and registry experience

To the editor: We recently read with interest the results published by Maccari et al. in "Crossed looks on the dermatologist's position and the patient's preoccupations as to psoriasis and pregnancy: preliminary results of the PREGNAN-PSO study." This study sheds light on knowledge gaps in a cohort of dermatologists' understanding on treatment of psoriasis in pregnancy. We echo their concerns about the lack of existing safety data on systemic treatments, particularly in regards to biologics, used for psoriasis in pregnancy. This article is protected by copyright. All rights reserved.